You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro ® (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Have there been any postmarketing adverse reactions reported with Mounjaro® (tirzepatide) use?
Adverse reactions reported during post-approval use of MOUNJARO include anaphylaxis, angioedema, acute pancreatitis, ileus, intestinal obstruction, severe constipation, pulmonary aspiration under anesthesia, acute or worsening renal failure, and alopecia.
See important safety information, including boxed warning, in the attached prescribing information.
Postmarketing Adverse Reactions with Mounjaro
The following adverse reactions have been reported during post-approval use of MOUNJARO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
- Hypersensitivity: anaphylaxis, angioedema
- Gastrointestinal: acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death, ileus, intestinal obstruction, severe constipation including fecal impaction
- Pulmonary: Pulmonary aspiration has occurred in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation
- Renal: acute renal failure or worsening of chronic renal failure, sometimes requiring hemodialysis
- Skin and Subcutaneous Tissue: alopecia.1
Enclosed Prescribing Information
Reference
1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
Date of Last Review: January 13, 2026